News & Videos - THERALINK TECHS INC. THER - English

You are currently viewing all stock exchange news of the financial instrument THERALINK TECHS INC. THER regarding all markets in English.

> News GlobeNewsWire published a news.

OncBioMune Announces Compelling Pre-clinical Data for its CD71-targeted Chemotherapy, PGT, in Models of Lung, Pancreatic and Ovarian Cancers • • GlobeNewsWire • Stocks

BATON ROUGE, La., July 15, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic prostate cancer vaccine immunotherapy and a CD71-targeted cancer therapy combining paclitaxel, gallium, and transferrin, or PGT, today announces the results of in vitro data for PGT in models of multi-drug resistant lung, pancreatic, and ovarian cancer. The Company...

Thank you Chart

> News GlobeNewsWire published a news.

OncBioMune Announces Initial In Vitro Proof-of-Concept Data for PGT in a Multi-Drug Resistant Ovarian Cancer Model • • GlobeNewsWire • Stocks

BATON ROUGE, La., May 30, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic prostate cancer vaccine immunotherapy and a CD71-targeted cancer therapy combining paclitaxel, gallium, and transferrin, otherwise known as PGT, today announces the results of initial in vitro data for PGT in a Multi-drug resistant ovarian cancer model. Cell...

Thank you Chart

> News GlobeNewsWire published a news.

OncBioMune Announces Agreement with CATO BioVentures as a Strategic Investor in Support of CD71-Targeted Therapy for Refractory Cancers • • GlobeNewsWire • Stocks

BATON ROUGE, La., May 01, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapy, is pleased to announce that it has received a letter of interest from CATO BioVentures, the venture capital affiliate of Cato Holding, a privately held family fund. This agreement is in support of the development...

Thank you Chart

> News GlobeNewsWire published a news.

Phase 2 Trial of OncBioMune’s Immunotherapy Cancer Vaccine ProscaVax for Prostate Cancer Patients in Active Surveillance Now Open for Enrollment • • GlobeNewsWire • Stocks

BATON ROUGE, La., March 19, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic prostate cancer vaccine immunotherapy and CD71-targeted cancer therapy, today announces that the Phase 2, randomized study of ProscaVax in treatment-naïve patients with clinically localized prostate cancer vs active surveillance is now open for enrollment. The first...

Thank you Chart

> News GlobeNewsWire published a news.

OncBioMune Announces Consulting Agreement with CATO Research LLC for Developing PGT, a Protein Drug Complex Targeting CD71 for Refractory Cancers • • GlobeNewsWire • Stocks

BATON ROUGE, La., Feb. 28, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapy, is pleased to announce that it has entered into a consulting agreement with CATO Research, LLC, a global provider of regulatory and clinical research services, effective immediately. This agreement relates to the...

Thank you Chart

> News GlobeNewsWire published a news.

Dr. Mitesh Borad Joins OncBioMune Scientific Advisory Board • • GlobeNewsWire • Stocks

BATON ROUGE, La., Jan. 28, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is pleased to announce the appointment of Mitesh J. Borad, M.D. to the Company’s Scientific Advisory Board, effective immediately. Dr. Borad is currently an Associate Professor of Medicine at Mayo Clinic...

Thank you Chart

> News GlobeNewsWire published a news.

OncBioMune Announces Former Puma Biotechnology Executive and Genentech Veteran Brian Barnett, M.D., as Chief Executive Officer • • GlobeNewsWire • Stocks

BATON ROUGE, La., Jan. 09, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, today announces that its Board of Directors has appointed Brian Barnett, M.D., as Chief Executive Officer. Prior to joining the Company, Dr. Barnett served at Puma Biotechnology, Inc. since August 2016...

Thank you Chart

> News GlobeNewsWire published a news.

Site Visit Planned for December 19, 2018 to Initiate Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer • • GlobeNewsWire • Stocks

BATON ROUGE, La., Dec. 07, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is pleased to provide an update on the Phase 2 clinical trial of ProscaVax being hosted at Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard University. In the clinical trial,...

Thank you Chart

> News GlobeNewsWire published a news.

OncBioMune Phase 2 Clinical Trial to Begin Enrollment; Company Announces Other Developments and Corporate Milestones • • GlobeNewsWire • Stocks

BATON ROUGE, La., Nov. 08, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, today provides an update on its upcoming Phase 2 clinical trials of ProscaVax for prostate cancer and other corporate developments. Phase 2 Trial, Early-Stage Prostate Cancer The Company’s lead Phase 2 trial...

Thank you Chart

> News GlobeNewsWire published a news.

OncBioMune CEO Dr. Jonathan Head Speaking at 2018 Global Summit on Genitourinary Malignancies • • GlobeNewsWire • Stocks

BATON ROUGE, La., Oct. 31, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is pleased to inform shareholders that the Company’s CEO, Dr. Jonathan Head, has been asked to present alongside other well renowned faculty speakers at Oncology Meeting Innovations’ 2018 Global Summit on...

Thank you Chart

> News GlobeNewsWire published a news.

OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Late Stage Prostate Cancer • • GlobeNewsWire • Stocks

BATON ROUGE, La., Oct. 16, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, today announces the signing of a work order with leading Contract Research Organization, Theradex Oncology (“Theradex”), detailing the scope to be provided by Theradex for a clinical trial titled, “A...

Thank you Chart

> News GlobeNewsWire published a news.

OncBioMune Advancing ProscaVax Towards Second Phase 2 Clinical Trial for Prostate Cancer with Protocol Submission to FDA • • GlobeNewsWire • Stocks

BATON ROUGE, La., Oct. 11, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is pleased to announce that the protocol for the planned Phase 2 clinical trial of ProscaVax for advanced prostate cancer to be hosted at Urology Clinics of North Texas (UCNT) has been submitted to the U.S. Food...

Thank you Chart

> News GlobeNewsWire published a news.

OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer • • GlobeNewsWire • Stocks

BATON ROUGE, La., Sept. 27, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, today provides a status update on the Phase 2 clinical trial of ProscaVax for early-stage prostate cancer. The Company is pleased to report that initial installments for the study have been made and the final...

Thank you Chart